Vertex registers Phase 1 VX-581 tablet study; adds detail on povetacicept IgAN extension

Vertex Pharmaceuticals' clinical trial registry shows two entries tied to its pipeline this week.

• Vertex registered a Phase 1, open-label, randomized, crossover study of VX-581 to evaluate the relative bioavailability of a tablet formulation compared with a suspension formulation. The trial is recruiting, with an actual start date of 2026-09-23 and an estimated primary and study completion date of 2026-10-27¹. The study enrolls 16 healthy male volunteers aged 18 to 55¹ at one site, Celerion in Tempe, Arizona¹.
• Vertex's Phase 3, single-arm, open-label extension study of povetacicept in immunoglobulin A nephropathy remains enrolling by invitation, with an actual start date of 2026-09-17 and estimated primary and study completion dates of 2029-12-28². The trial plans to enroll 605 participants², who will receive povetacicept every 4 weeks (Q4W) for 104 weeks², with eligibility requiring participants to have completed the Week 104 visit in the parent study VX24-AIS-D08 (NCT06564142) and not permanently discontinued study drug².